Ypsomed streamlines executive management and expands European sales team
Richard Fritschi, CEO of the Ypsomed Group, comments: "The overwhelming interest and the huge demand in the market for the new mylife(TM) OmniPod® insulin patch pump exceeds our expectations. The insulin patch pump has no infusion set and offers patients with diabetes a greater degree of freedom and simplicity in use compared with conventional insulin pump therapy, while at the same time opening up new possibilities in the treatment of infants and young people. Consequently, Ypsomed will further expand its diabetes sales organisation in Europe over the coming months. At the same time we strive to continuously improve productivity in Switzerland and adapt the organisational structure as needed."
The Ypsomed Group is a leading independent developer and manufacturer of injection systems for selfmedication and a wellknown diabetes specialist with more than 25 years' experience. Ypsomed is an innovation and technology leader with an extensive patent portfolio and is the preferred partner of pharmaceutical and biotech companies in the selfmedication sector. The Ypsomed Group, which emerged in 2003 with at the time 550 employees from the wellknown Disetronic Group, today employs approximately 1'200 employees. The Ypsomed Group has its headquarters in Burgdorf, Switzerland, and manufacturing sites in Burgdorf, Solothurn, Grenchen and the Czech Republic as well as leading independent diabetes product sales subsidiaries in Germany, France, Switzerland, the Netherlands, the Nordic countries as well as in India and since April 2010 in Great Britain.